scholarly journals NGO war on biotechnology

2005 ◽  
Vol 11 (3) ◽  
Author(s):  
Henry I Miller ◽  
Gregory Conko

Discussions of the risks and benefits of recombinant DNA technology, or 'genetic modification' (GM), should occur within the context of experience with older, 'conventional' techniques for genetic improvement. But critics' alarmist reports and commentaries invariably emphasise the things that might go wrong only with recombinant DNA-modified organisms, while studiously avoiding the essential broader context. They ignore vast amounts of data, including literally millennia of experience with less precise methods used for genetic modification, and they continue to deny the well-established scientific consensus that no unique risks attend the use of recombinant DNA techniques. They promulgate the perception that recombinant DNA technology is unproven, untested and unregulated – and promote an approach to regulation in which there is an inverse relationship between degree of scrutiny and risk. The disproportionate regulation of the products of recombinant DNA technology needlessly raises the cost of research and development, while it fails to advance consumer or environmental safety. The question we must ask is not whether regulation generally is or is not justified, but rather what should be regulated and how? The use of certain techniques – in particular, those that are the most precise and predictable – as a trigger for regulation cannot be justified scientifically. Regulatory efforts should be redirected to focus oversight on new organisms that express characteristics likely to pose significant risk, regardless of the methods used in their development, while leaving relatively low-risk traits of both classical and molecular genetic modification unburdened by costly regulation.

Genome ◽  
1989 ◽  
Vol 31 (2) ◽  
pp. 536-540 ◽  
Author(s):  
Thomas D. Petes ◽  
Peter Detloff ◽  
Sue Jinks-Robertson ◽  
S. Renee Judd ◽  
Martin Kupiec ◽  
...  

The development of methods to isolate eukaryotic genes, alter these genes in vitro and reintroduce them into the cell has had a major impact on the study of recombination in the yeast Saccharomyces cerevisiae. In this paper we discuss how recombinant DNA techniques have been employed in the study of recombination in yeast and the results that have been obtained in these studies.Key words: recombination, Saccharomyces cerevisiae, gene conversion, repeated genes.


Author(s):  
Zumrut Begum Ogel

Rennet, traditionally obtained from calves, is non-vegeterian and unethical due to the slaughter of unweaned animals. Chymosin is highly specific to the Phe105-Met106 bond of κ-casein and has low proteolytic activity. Microbial aspartic proteases can partly replace chymosin. However, recombinant DNA technology has allowed chymosin itself to be produced by bacteria, yeast, and molds. Not only rennet from calf, but from animals like goat kid, lamb, buffalo, camel, and others can be used in cheesemaking. Chymosins of these animals can be cloned and successfully expressed in microorganisms and can be employed in the production of novel as well as traditional cheese products from the milk of camel, goat, and even horse and donkey. This chapter outlines the recombinant DNA techniques applied over the past few years to improve the microbial production of recombinant rennet, from animals and plants.


1992 ◽  
Vol 38 (Special) ◽  
pp. 263-266
Author(s):  
O. IFUKU ◽  
S. HAZE ◽  
J. KISHIMOTO ◽  
M. YANAGI

PEDIATRICS ◽  
1984 ◽  
Vol 74 (3) ◽  
pp. 408-411
Author(s):  
Stephen D. Cederbaum

Seldom has a scientific or biomedical break-through evoked the awe, controversy, or sheer incredulity that has accompanied the developments in the field of recombinant DNA technology or more popularly, gene cloning and genetic engineering. Now little more than one generation after Avery, et al1 demonstrated that genes were encoded in DNA and Watson and Crick2 interpreted the structure of these molecules, genes are being cut, manipulated, and recombined to produce unprecedented new insights into genetics and molecular biology and the prospect of gene therapy. These developments have not occurred without anxiety to both scientists and laymen. At the moment, neither the most apocalyptic fears nor the most optimistic dreams appear to be imminent, although I believe that the dreams are closer to fulfillment than the fears. Recombinant DNA technology is already having great impact in hematology, oncology, endocrinology, immunology, and infectious disease and will soon play an important role in other medical subspecialities as well. In none, however, will it have quite the same impact as in genetics because DNA is the material that genetics "is all about." The cloning and study of phenylalanine hydroxylase is one of the first instances in which this technology has important implications in the diseases traditionally classified as inborn errors of metabolism. In order to understand and appreciate the presentation by Woo on phenylalanine hydroxylase as well as the many future papers that will play so vital a role in all of our professional lives, it is necessary to acquire the basic vocabulary of the field.


Sign in / Sign up

Export Citation Format

Share Document